Compound Detail
CHEMBL518924
MAVORIXAFOR 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL518924 |
| Name | MAVORIXAFOR |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | WVLHHLRVNDMIAR-IBGZPJMESA-N |
| Therapeutic | ✓ Yes |
7
Targets
21
Activities
3
Assay Types
30
PK Parameters
20
Publications
11
Known Names
7
Indications
1
Mechanisms
Molecular Properties
349.5
MW (Da)
3.58
ALogP
4
HBA
2
HBD
70.8
PSA (Ų)
0.64
QED
0
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2024 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| C-X-C chemokine receptor type 4 antagonist | ANTAGONIST | C-X-C chemokine receptor type 4 | ✓ | ✓ |
Indications
Neoplasms Neutropenia Breast Neoplasms Carcinoma, Renal Cell HIV Infections Melanoma Waldenstrom Macroglobulinemia
ATC Classification
L03AX24
mavorixafor
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSTIMULANTS
Activity Summary
IC50 17 meas. best 8.52
EC50 3 meas. best 7.82
Ki 1 meas. best 7.64
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Human immunodeficiency virus 1 CHEMBL378 | IC50 | 8.52 | 8.115 | 3.0 | 6 |
| C-X-C chemokine receptor type 4 CHEMBL2107 | IC50 | 8.3 | 8.0 | 5.0 | 4 |
| Human immunodeficiency virus 1 CHEMBL378 | EC50 | 7.82 | 7.5133 | 15.0 | 3 |
| C-X-C chemokine receptor type 4 CHEMBL2107 | Ki | 7.64 | 7.64 | 23.0 | 1 |
| Cytochrome P450 2D6 CHEMBL289 | IC50 | 5.8 | 5.7933 | 1600.0 | 3 |
| D(2) dopamine receptor CHEMBL217 | IC50 | 5.39 | 5.39 | 4100.0 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 5.28 | 5.28 | 5200.0 | 1 |
| Muscarinic acetylcholine receptor M2 CHEMBL211 | IC50 | 5.12 | 5.12 | 7500.0 | 1 |
| Mu-type opioid receptor CHEMBL233 | IC50 | 4.92 | 4.92 | 12000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 2.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 358.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 1695.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 6716.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 937.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 1590.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 7662.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 5.8 | - | Rattus norvegicus |
| AUC | 3.4 | - | Canis lupus familiaris |
| AUC | 58.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 934.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 1643.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 1205.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 100.6 | ng.hr.mL-1 | Mus musculus |
| AUC | 415.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 35.1 | ng.hr.mL-1 | Mus musculus |
| AUC | 101.0 | ng.hr.mL-1 | Mus musculus |
| CL | 3.7 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 1.3 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 30.51 | uL.min-1.(10^6cells)-1 | Rattus norvegicus |
| CL | 46.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 1776.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 120.5 | mL.min-1.kg-1 | Mus musculus |
| CL | 120.5 | mL.min-1.kg-1 | Mus musculus |
| Cmax | 454.96 | nM | Homo sapiens |
| Cmax | 789.74 | nM | Homo sapiens |
| Cmax | 2847.09 | nM | Homo sapiens |
| Cmax | 4017.4 | nM | Homo sapiens |
| Cmax | 1319.1 | nM | Homo sapiens |
| Cmax | 2269.09 | nM | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine